NCT07131722 2026-01-23
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
PRG Science & Technology Co., Ltd.
Phase 1/2 Not yet recruiting
Clinical Trials
5 trialsNCT05130866 2025-10-07
POPLAR-NF2
Recursion Pharmaceuticals Inc.
Phase 2/3 Terminated
NCT04759781 2024-07-08
MERLIN_001
SkylineDx
Active not recruiting
NCT03710564 2023-01-30
MERLIN
Novartis
Phase 3 Terminated
NCT00911248 2019-04-12
PTC299 for Treatment of Neurofibromatosis Type 2
PTC Therapeutics
Phase 2 Terminated